Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer

Élias, Dominique; Benizri, Emmanuel; Pocard, Marc; Ducreux, Michel; Boige, Valérie; Lasser, P

doi:10.1016/j.ejso.2006.03.013

Cited by 119 publications

(79 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, because the prognosis for colorectal cancer patients with limited resectable liver metastases after hepatic surgery and current chemotherapeutic regimens is reasonable, some centres will use liver surgery, crs, hipec, and systemic chemotherapy to treat patients with up to 3 peripherally localized and resectable liver metastases and limited ptc. The morbidity and long-term results in such patients are not different from those of colorectal ptc patients without liver metastases (to be discussed shortly) [12][13][14] . Infiltration of the liver capsule by peritoneal tumour should be differentiated from parenchymal liver metastases.…”

Section: Patient Selectionmentioning

confidence: 96%

“…As already discussed, patients with limited ptc and fewer than 3 resectable liver metastases can also be good candidates for hipec, with a reasonable possibility of achieving prolonged survival [12][13][14] .In a recent case-control study 13 , 37patients with ptc and liver metastases were matched with 61 patients having ptc alone. All underwent crs, resection of liver metastases (when present), and hipec.…”

Section: Colorectal Cancermentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Peritoneal Surface Malignancies with Hyperthermic Intraperitoneal Chemotherapy—Current Perspectives

2016

View full text Add to dashboard Cite

Peritoneal carcinomatosis (ptc) represents advanced malignant disease and has generally been associated with a grim prognosis. Peritoneal surface malignancy is often the major source of morbidity and mortality; it is of major concern in cancer management. Although ptc is categorized as metastatic disease, it represents a special disease pattern considered to be a locoregional disease limited to the abdominal cavity. The combination of cytoreductive surgery (crs) and intraoperative hyperthermic intraperitoneal chemotherapy (hipec) has successfully been used as locoregional treatment for selected patients with ptc from gastric, colorectal, and ovarian cancer; with mesothelioma; and with pseudomyxoma peritonei. In the prophylactic setting, hipec can also be used to prevent ptc in high-risk patients, and the first results of the "second-look" approach are promising. Patient selection-in which the risks of perioperative morbidity and mortality, which are analogous to those for any other major gastrointestinal surgery, are assessed-is of utmost importance. Those risks have to be weighed against the anticipated survival benefit, which depends mainly on tumour biology, extent of disease, and probability of achieving complete crs. The present review discusses the principles of crs and hipec, the most significant recent clinical data, and current perspectives concerning the application of this treatment modality in various malignancies. Ongoing trials and future directions are noted. It appears that the combination of crs and hipec is an indispensable tool in the oncologist's armamentarium.

show abstract

Section: Patient Selectionmentioning

confidence: 96%

Section: Colorectal Cancermentioning

confidence: 99%

Treatment of Peritoneal Surface Malignancies with Hyperthermic Intraperitoneal Chemotherapy—Current Perspectives

2016

View full text Add to dashboard Cite

show abstract

“…Liver metastases may also be a contraindication except for colorectal carcinomatosis. Several studies have shown that the presence of few (one to three) liver metastases did not influence survival if they could be surgically removed for PC from colorectal cancer [47,48]. For conditions where there is no cut off for PCI, the contraindications are & Extensive bowel resection that is likely to compromise the future quality of life e.g.…”

Section: Contra-indications To Crs and Hipecmentioning

confidence: 99%

Cytoreductive Surgery and Peritonectomy Procedures

Mehta

Bhatt

Gléhen

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become widely accepted as an effective method of treating peritoneal metastases (PM) from various cancers. CRS performed with the goal of removing all the macroscopic disease and comprises of peritonectomy procedures and visceral resections. CRS is a technically challenging surgery that requires a considerable amount of skill and appropriate patient selection. This article is a review of the techniques and current recommendations for performing CRS.

show abstract

“…It should be underlined, however, that the reported LR combined with CS + HIPEC are classified as minor procedures, normally associated with lower risk of complications. Although no liver specific complications (biloma, bleeding, abscess) are generally reported, a higher risk of systemic toxicity has been noted after major LR [36] ; the hypothesis that transient liver failure leads to a decreased drug inactivation and therefore a higher systemic toxicity should be further tested.…”

Section: Assessment Of Morbidity and Mortalitymentioning

confidence: 99%

Treatment of liver metastases in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis

Sommariva¹

2017

JCMT

View full text Add to dashboard Cite

How to cite this article: Sommariva A. Treatment of liver metastases in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. J Cancer Metastasis Treat 2017;3:362-7. Cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have gained increasing consensus in treatment of peritoneal carcinomatosis from colorectal cancer. The presence of liver metastases is generally considered a contraindication for CS + HIPEC, as hepatic involvement no longer represents a loco-regional aspect of disease. Despite this, liver resection (LR) has been tested in selected cases in combination with CS + HIPEC for treatment of peritoneal carcinomatosis with liver metastasis. Relevant studies on this topic were identified through a search in the electronic PubMed database, using the appropriate keywords. CS + HIPEC + LR allows similar outcomes in terms of survival and morbidity with respect to CS + HIPEC, especially in patients with low tumor load. CS + HIPEC + LR represents a reasonable approach for patients with peritoneal carcinomatosis and liver metastases from colorectal cancer. Patients should be selected in high volume tertiary centres, preferably in the context of a prospective trial. Quick Key words:Colorectal cancer, peritoneal carcinomatosis, liver metastases, hyperthermic intraperitoneal chemotherapy, liver resection ABSTRACTArticle history:

show abstract

Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer

Cited by 119 publications

References 20 publications

Treatment of Peritoneal Surface Malignancies with Hyperthermic Intraperitoneal Chemotherapy—Current Perspectives

Treatment of Peritoneal Surface Malignancies with Hyperthermic Intraperitoneal Chemotherapy—Current Perspectives

Cytoreductive Surgery and Peritonectomy Procedures

Treatment of liver metastases in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis

Contact Info

Product

Resources

About